More prospective studies (e.g., stratified analysis of chemotherapy efficacy based on HER2 status), as well as in-depth molecular mechanistic studies, are warranted to fully elucidate the role of HER2 in CRC chemotherapy sensitivity and optimize individualized treatment strategies. This evidence concerns the gene ERBB2 and colorectal carcinoma.